KIF11 and breast cancer: Secondly, among thiadiazoline-based Eg5 inhibitors, 2 and 41, simultaneously modulating several key processes of breast cancer spread and progression, such as cell proliferation, invasiveness, migration, ECM remodeling, and angiogenesis, along with apoptosis or necrosis occurrence, represent a new drug strategy to control breast cancer.